지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술대회자료
- 저자정보
- 발행연도
- 2017.3
- 수록면
- 29 - 29 (1page)
이용수
초록· 키워드
오류제보하기
등록된 정보가 없습니다.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .05
-
Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
Gut and Liver
2022 .01
-
Neoadjuvant treatment is always justified for small PDAC, especially for clinical T1? Debate from the position of Cons
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Artery first approach pancreaticoduodenectomy with segmental resection and reconstruction of SMV for borderline resectable PDAC after neoadjuvant chemotherapy
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Neoadjuvant treatment is always justified for small PDAC, especially for clinical T1? - Debate from the position of Pros
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Comments on - Neoadjuvant Chemo-radiation with IMRT in Resectable and Borderline Resectable Pancreatic Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
The Role of Neoadjuvant Treatment in Resectable Pancreatic Cancer
대한외과학회 학술대회 초록집
2019 .10
-
The change of clinical stage after neoadjuvant chemotherapy in prediction of prognosis for borderline resectable and locally advanced pancreatic cancer
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Great Debates: Which is the Best? Resectable pancreatic cancer: Neoadjuvant treatment first
대한임상종양학회 학술대회지
2019 .02
-
Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-analysis
대한외과학회 학술대회 초록집
2022 .11
-
Clinical significance of defining borderline resectable pancreatic cancer
한국간담췌외과학회 학술대회지
2017 .03
-
Does Current Staging System Applicable for Borderline Resectable or Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy?
대한외과학회 학술대회 초록집
2022 .05
-
Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
Gut and Liver
2022 .01
-
Validation of anatomical and biological definition of borderline resectable cancer according to the 2017 international consensus for survival in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma undergoing upfront surgery
대한임상종양학회 학술대회지
2022 .02
-
Validation of anatomical and biological definition of borderline resectable pancreatic cancer according to the 2017 international consensus for survival in patients with resectable and borderline rese
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Surgical strategy for borderline resectable pancreatic cancer
한국간담췌외과학회 학술대회지
2017 .03
-
Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
Annals of Hepato-Biliary-Pancreatic Surgery
2019 .05
-
Current Definition of Borderline Resectable Pancreatic Cancer and Its Limitation
한국간담췌외과학회 학술대회지
2017 .03
-
Role of neoadjuvant treatment for resectable pancreatic ductal adenocarcinoma
한국간담췌외과학회 학술대회지
2017 .03
-
Clinical Outcomes of the Borderline Resectable Pancreatic Cancer according to the Neoadjuvant Chemo-Regimens: Gemcitabine vs. FOLFIRINOX
대한외과학회 학술대회 초록집
2019 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2018-514-000983179